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A B S T R A C T
Background: Elevated plasma vitamin B12 levels (cobalamin, Cbl) are associated with increased short-
term cancer risk among patients referred for this laboratory measurement. We aimed to assess prognosis
in cancer patients with elevated plasma Cbl.
Methods: We conducted a population-based cohort study using data from Danish medical registries
during 1998–2014. The study included 25,017 patients with a cancer diagnosis and Cbl levels of 200–
600 pmol/L (reference/normal range), 601–800 pmol/L and >800 pmol/L measured up to one year prior to
diagnosis, and a comparison cohort of 61,988 cancer patients without a plasma Cbl measurement.
Patients treated with Cbl were excluded. Survival probability was assessed using Kaplan–Meier curves.
Mortality risk ratios (MRR) were computed using Cox proportional hazard regression, adjusted for age,
sex, calendar year, cancer stage and comorbidity, scored using the Charlson comorbidity index.
Results: Survival probabilities were lower among patients with elevated Cbl levels than among patients
with normal levels and among members of the comparison cohort [(1-year survival,%) Cbl: 200–
600 pmol/L: 69.3%; 601–800 pmol/L: 49.6%; >800 pmol/L: 35.8%; comparison cohort: 72.6%]. Thirty-day
mortality was elevated for patients with Cbl levels of 601–800 pmol/L or >800 pmol/L, compared to
patients with levels of 200–600 pmol/L [(MRR (95% conﬁdence interval): 601–800 pmol/L vs. 200–
600 pmol/L: 1.9 (1.6–2.2); >800 pmol/L vs. 200–600 pmol/L: 2.7 (2.4–3.1)]. This association remained
robust for 31–90-day and 91–365-day mortality, showing similar dose-response patterns.
Conclusion: Cancer patients with elevated Cbl levels had higher mortality than those with normal Cbl
levels. These ﬁndings may have clinical signiﬁcance for assessing the prognosis of cancer patients.
ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Low circulating vitamin B12 levels (cobalamin, Cbl) are
associated with conditions such as anemia and neuropsychiatric
disorders [1], while high Cbl levels have been linked to a number of
other diseases, including cancer [2]. In a large population-based
study, we recently showed that elevated plasma Cbl levels were
associated with increased cancer risk among patients referred for
this laboratory test [3]. This study and others [4–8] have enhanced
awareness of the clinical implications of high Cbl levels.Abbreviations: ATC, anatomical therapeutic chemical; AUPD, Aarhus University Presc
conﬁdence interval; CPR, Civil Personal Registration; DCR, Danish Cancer Registry; DNRP,
10th revision; LABKA, clinical laboratory information system research database; MRR, 
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E-mail addresses: jfba@clin.au.dk (J.F.H. Arendt), df@clin.au.dk (D.K. Farkas), lap@clin
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1877-7821/ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article unA few previous studies have focused on the prognostic impact of
elevated Cbl levels. Some have shown that high Cbl levels were
associated with increased mortality risk, both among patients with
cancer [9–14] and among patients without cancer [11,15–19]. Other
studies do not support these ﬁndings [20–22]. Previous studies on
mortality among cancer patients with elevated Cbl levels were
limited by small sample size (61 to 329 patients) [9–14], and only
one was a multi-center study [12]. Also, all patients were
diagnosed with cancer prior to plasma Cbl measurement, thereby
restricting the study populations to hospitalised cancer patients.ription Database; Cbl, cobalamin, vitamin B12; CCI, Charlson comorbidity index; CI,
 Danish National Registry of Patients; ICD-10, international classiﬁcation of diseases,
mortality risk ratio; NPU, nomenclature, properties and units.
ospital, Olof Palmes Allé 43-45, DK8200 Aarhus N, Denmark. Fax: +45 87 16 72 15.
.au.dk (L. Pedersen), e.nexo@dadlnet.dk (E. Nexo), hts@clin.au.dk (H.T. Sørensen).
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levels, we conducted a population-based cohort study to investi-
gate survival among cancer patients with a plasma Cbl measure-
ment prior to cancer diagnosis. We hypothesised that elevated Cbl
levels would be associated with poorer survival.
2. Materials and methods
2.1. Design and data sources
This population-based cohort study was based on data from
Northern Denmark from medical registries during the period
from January 1 1998 through December 31 2014. The following
data sources were used: the Clinical Laboratory Information
System Research Database (LABKA) [23], the Aarhus University
Prescription Database (AUPD) [24], the Danish Cancer Registry
(DCR) [25] and the Danish National Registry of Patients (DNRP)
[26]. The Danish Civil Registration System, established in 1968,
assigns a Civil Personal Registration (CPR) number to all
residents, allowing unambiguous individual-level linkage of
data among all Danish registries [27]. The Danish Civil
Registration System also maintains data on vital status and
migration. It provided dates of death for this study until
December 31 2014. For a detailed description of the registries
and databases and the codes used in this study, please see
Supplementary data.
For the current study we used the DCR [25] to retrieve data on
cancer diagnosis and cancer stage for patients diagnosed from
January 1 2001 through November 30 2013 in Northern Denmark.
We identiﬁed all patients in the LABKA [23] database with a
plasma Cbl measurement of 200 pmol/L or more (271 pg/mL, the
lower reference limit in Northern Denmark [28]) from January 1
2000 through November 30 2013. Thus, the Cbl measures were
derived from routine clinical testing performed upon request from
the clinician at the time of testing.
The AUPD [24] provided data on prescriptions for Cbl drugs.
Patients were classiﬁed as having received Cbl therapy if they had
one or more prescriptions for Cbl therapy drugs recorded in the
AUPD up to two years prior to measurement of their plasma Cbl
levels. In Denmark, treatment with Cbl drugs at doses >0.5 mg [29]
is only available by prescription.
In order to assess possible confounding from comorbidities, we
retrieved data from the DNRP [26] on all diagnoses prior to the
cancer diagnosis. We also retrieved data on hospital treatment
with Cbl drugs.
2.2. Study cohorts
Patients in Northern Denmark with a ﬁrst cancer diagnosis
recorded in the DCR from January 1 2001 through November 30
2013 and a plasma Cbl record in the LABKA database within one
year prior to the cancer diagnosis date (index date) were included
in the study as the patient cohort. For patients with more than
one recorded plasma Cbl level, we used the record closest to the
index date. Patients were excluded if they received Cbl therapy
within two years prior to measurement of plasma Cbl levels
(n = 3009).
A comparison cohort from Northern Denmark was sampled
from the DCR and matched to patients with a Cbl measurement by
sex, age (10-year intervals), calendar period of diagnosis (5-year
intervals) and cancer type. Each patient with a Cbl measurement
was matched with up to 3 persons in the comparison cohort.
Members of the patient cohort and the comparison cohort were
followed from the index date until death, emigration or 31
December 2014, whichever came ﬁrst.2.3. Statistical analyses
We disaggregated patients with Cbl measurements into three
groups according to plasma Cbl levels: 200–600 pmol/L
(271–813 pg/mL, population reference range [28], normal Cbl
levels), 601–800 pmol/L (814–1084 pg/mL) and >800 pmol/L
(>1084 pg/mL). Using the Cochran–Armitage test [30,31], we
tested for trends in distribution of sex, cancer types, cancer stages
and comorbidity across the three Cbl level groups. We focused
speciﬁcally on patients with elevated Cbl levels and examined a
possible dose–response association. We ﬁtted a cubic spline curve
using plasma Cbl levels in 5%-percentiles to further assess any
dose–response association with 1-year survival.
TNM stage for solid tumors and Ann Arbor stage for lymphomas
were divided into two stage categories: localised and non-
localised. Stage was not deﬁned for lymphatic leukemia and
malignant myeloid diseases. Therefore, these two cancers were
analysed separately and not including stage, and also not included
in the imputation model for missing stage (see below). Overall
survival was assessed using Kaplan–Meier curves. We stratiﬁed the
Kaplan–Meier curves according to cancer stage. We computed
survival probability estimates at 30 days, 90 days and 365 days, 2
years, 5 years and 10 years after cancer diagnosis. Using log-rank
tests, we compared survival among patients in the three Cbl level
groups and also compared the survival between members of the
comparison cohort and the patient cohort. Cox proportional
hazards regression was used to evaluate mortality risk for patients
in the three Cbl level groups, using the group with Cbl levels of
200–600 pmol/L as reference. Mortality risk ratios (MRR) with
corresponding 95% conﬁdence intervals (CI) were computed by
comparing mortality risks among the three groups. The regression
analyses were adjusted for the following potential confounding
factors: sex, age (continuous), calendar year, cancer stage and
Charlson Comorbidity Index (CCI) score [32]. Cancer and cancer
stage were omitted from the CCI score. We classiﬁed patients in
each of the three Cbl level groups according to three CCI categories:
low = score of 0, medium = score of 1–2 and high = score of 3. We
also stratiﬁed patients in each of the three Cbl level groups
according to age (0–40, 41–60, 61–80 and 81 years), calendar year
of cancer diagnosis, sex and cancer stage (not adjusting for the
variable used for stratiﬁcation). All results from the Cox regression
analyses were also disaggregated according to length of follow-up:
30 days, 31–90 days, 91–365 days, 366 days-2 years, 3–4 years and
5 years. We also computed MRRs for speciﬁc cancer types,
adjusted for all of the above covariates. We tested for equality
between MRR estimates for 601–800 pmol/L vs. 200–600 pmol/L
and MRR estimates for >800 pmol/L vs. 200–600 pmol/L by using
Wald chi-square test. The proportional hazards assumption was
fulﬁlled based on visual evaluation of log–log plots.
Cancer stage was missing in 23% of the patient and the
comparison cohorts combined. To account for this, we used
multiple imputations with chained equations and created multiple
different complete datasets. This approach has been shown to
produce estimates with less bias and higher precision [33], under
the assumption of data being missing at random. This has also been
shown to be valid for missing cancer stage in medical registries
[34] and in prognostic studies [35]. This yielded a model consisting
of the following covariates, used for prediction of cancer stage: sex,
age (continuous), calendar year, cancer type, plasma Cbl levels
(continuous), CCI score, length of follow-up and death (yes/no). We
then computed 30 complete datasets, and performed the analyses
described above for each dataset. The estimates were then
combined into one single estimate with corresponding 95%
conﬁdence intervals using the Rubin's rule [33]. To validate the
model, we compared estimates between the complete case
analyses and the imputed model.
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(SAS Institute Inc., Cary, NC, USA). All tests were two-sided and
considered statistically signiﬁcant if p < 0.05. The study was
approved by the Danish Data Protection Agency (record number:
2013-41-1924). The use of registry data for research in Denmark
does not require ethical approval.
3. Results
3.1. Descriptive data
The study included 25,017 patients with a Cbl measurement
within one year prior to their cancer diagnosis. Among these, 3443
(14%) had high Cbl levels (>600 pmol/L). A total of 61,988 persons
with cancer were included in the comparison cohort. The sex
distribution was 50.6% male among patients with a Cbl measure-
ment and 51.3% male among persons in the comparison cohort.
Median time in days (interquartile range) from Cbl measurement
to cancer diagnoses for the patient cohort was as follows: 200–
600 pmol/L: 57 (16–168); 601–800 pmol/L 32 (8–112) and
>800 pmol/L: 16 (3–57). Table 1 shows the major types of cancer
in the patient cohort with Cbl measurements and in the
comparison cohort. In the comparison cohort, cancer stage was
missing or unknown in 23% of the persons, while the proportionTable 1
Characteristics of cancer patients with a Cbl measurement and of the comparison coho
Cohort with plasma Cbl measurements (pmo
200–600 601–800 
Number of patients, n 21,574 1,795 
Sex (male), % 51.3 46.5 
Age at diagnosis, years
Median (range) 71 (3–100) 71 (3–104) 
Year of diagnosis, n (%)
2001–2005 4,179 (19.4) 323 (18.0) 
2006–2010 9,951 (46.1) 773 (43.1) 
2011–2013 7,444 (34.5) 699 (38.9) 
Cancer type, n (%)b
Gastric 430 (2.0) 29 (1.6) 
Colorectal 3,088 (14.3) 190 (10.6) 
Liver 181 (0.8) 66 (3.7) 
Pancreas 567 (2.6) 121 (6.7) 
Lung 2,636 (12.2) 300 (16.7) 
Breast 1,470 (6.8) 102 (5.7) 
Prostate 2,348 (10.9) 91 (5.1) 
Kidney 487 (2.3) 33 (1.8) 
Urinary bladder 468 (2.2) 35 (1.9) 
Non-Hodgkin lymphoma 1,230 (5.7) 79 (4.4) 
Lymphatic leukemia 396 (1.8) 26 (1.4) 
Malignant myeloid diseases 694 (3.2) 143 (8.0) 
Brain and other CNS tumors 325 (1.5) 10 (0.6) 
Other cancers 7,254 (33.6) 570 (31.8) 
Cancer stage, n (%)
Localised 9,082 (42.1) 539 (30.0) 
Non-localised 6,887 (31.9) 695 (38.7) 
Unknown/missingc 5,605 (26.0) 561 (31.3) 
CCI score, n (%)b
CCI = 0 (Low) 11,951 (55.4) 871 (48.5) 
CCI = 1-2 (Medium) 7,476 (34.7) 677 (37.7) 
CCI  3 (High) 2,147 (10.0) 247 (13.8) 
Abbreviations: Cbl: cobalamin; CCI: Charlson comorbidity index.
a Cochran–Armitage test for trend for age, sex, cancer type, cancer stage and CCI sco
b Percentages do not total 100% due to rounding.
c Also includes lymphatic leukemia and malignant myeloid diseases where stage waranged from 26% to 42% in the patient cohort. A higher proportion
of non-localised cancer was found with higher Cbl levels. Variation
in CCI scores among the three Cbl level groups reached statistical
signiﬁcance, but with no clear trend.
3.2. Cancer survival
The Kaplan–Meier curve in Fig. 1A depicts the overall survival of
members of the comparison cohort and patients in the three Cbl
level groups. The ﬁgure shows that patients with a Cbl measure-
ment had a signiﬁcantly lower survival probability than members
of the comparison cohort (p < 0.0001), and that survival decreased
substantially with higher Cbl levels (p < 0.0001 comparing survival
between different Cbl level groups). The difference in survival
remained similar when stratifying according to cancer stage
(Fig. 1B and C). The spline regression analysis is shown in Fig. S1
(see Supplementary material). The analysis showed that 1-year
survival was decreasing at Cbl levels near the upper reference limit
of 600 pmol/L and above.
Table 2 shows the survival probability at 30 days, 90 days and
365 days after cancer diagnosis among patients in the three Cbl
level groups and among members of the comparison cohort. When
testing for trend in survival rates between the three Cbl level
groups, we observed trends toward lower survival with higher Cblrt, Northern Denmark, 2001–2013.
l/L) P for trenda Comparison cohort
>800
1,648 61,988
45.6 <0.0001 51.3
71 (4–100) 70 (3–102)
367 (22.3) 0.0513 13,692 (22.1)
727 (44.1) 0.0156 28,667 (46.2)
554 (33.6) 0.3629 19,629 (31.7)
38 (2.3) 0.75 1,194 (1.9)
163 (9.9) <0.0001 8,103 (13.1)
80 (4.9) <0.0001 551 (0.9)
147 (8.9) <0.0001 1,817 (2.9)
225 (13.7) 0.0002 8,148 (13.1)
78 (4.7) 0.0003 4,942 (8.0)
60 (3.6) <0.0001 7,292 (11.8)
37 (2.2) 0.62 1,343 (2.2)
38 (2.3) 0.94 1,528 (2.5)
70 (4.2) 0.0016 2,539 (4.1)
24 (1.5) 0.14 824 (1.3)
256 (15.5) <0.0001 872 (1.4)
4 (0.2) <0.0001 836 (1.3)
428 (26.0) <0.0001 21,999 (35.5)
302 (18.3) <0.0001 28,195 (45.5)
655 (39.7) <0.0001 20,764 (33.5)
691 (41,9) <0.0001 13,029 (21.0)
848 (51.5) <0.0001 39,562 (63.8)
585 (35.5) 0.09 18,713 (30.2)
215 (13.0) <0.0001 3,713 (6.0)
re across the three Cbl level groups.
s not deﬁned.
Fig.1. Kaplan–Meier curves showing survival as a percentage in the comparison cohort (—) and in the patient cohort, disaggregated according to Cbl levels of 200–600 pmol/L
(- - -), 601–800 pmol/L () and >800 pmol/L (-). These ﬁgures are based on multiple imputations to account for missing cancer stage. Lymphatic leukemia and malignant
myeloid diseases were not included in the analyses. Fig.1A: overall survival; Fig.1B: survival for patients with localised cancer; Fig.1C: survival for patients with non-localised
cancer.
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localised and non-localised cancer. The differences in survival with
higher Cbl levels were similar after 2, 5 and 10 years (data not
shown). When assessing survival using complete case analysis, we
observed slighter lower survival probabilities and minor differ-
ences in survival with increasing plasma Cbl levels, compared to
imputed data. For survival probabilities based on complete case
analysis, please see Supplementary Table S2.Table 2
Survival probability in percentages (with 95% CIs) for cancer patients with different
Cbl levels and for the comparison cohort, disaggregated according to follow-up
time. Estimates for both overall survival and survival according to cancer stage are
shown. These results are based on multiple imputations to account for missing
cancer stage (not including lymphatic leukemia and malignant myeloid diseases).
Survival probability by follow-up, % (95% CI)
30 days 90 days 365 days
Comparison cohort
Overall 94.0 (93.8–94.2) 86.8 (86.5–87.1) 72.6 (72.2–72.9)
Localised cancer 98.2 (98.1–98.4) 96.0 (95.8–96.3) 89.8 (89.4–90.2)
Non-localised cancer 88.6 (88.1–89.0) 75.1 (74.5–75.7) 50.7 (49.8–51.5)
Patient cohort
Overall
Plasma Cbl levels (pmol/L)
200–600 93.2 (92.8–93.5) 84.7 (84.2–85.2) 69.3 (68.7–70.0)
601–800 84.9 (83.1–86.6) 70.1 (67.7–72.3) 49.6 (47.1–52.1)
>800 76.8 (74.4–79.0) 56.9 (54.2–59.6) 35.8 (33.2–38.4)
P for trenda <0.0001 <0.0001 <0.0001
Localised cancer
Plasma Cbl levels (pmol/L)
200–600 97.9 (97.6–98.2) 94.9 (94.4–95.4) 87.5 (86.7–88.2)
601–800 95.4 (93.5–97.3) 90.1 (87.5–92.6) 77.5 (74.0–81.0)
>800 92.0 (88.7–95.3) 85.3 (81.2–89.5) 71.6 (66.6–76.6)
P for trenda <0.0001 <0.0001 <0.0001
Non-localised cancer
Plasma Cbl levels (pmol/L)
200–600 87.6 (86.9–88.3) 72.6 (71.5–73.7) 47.9 (46.4–49.4)
601–800 77.8 (75.0–80.6) 56.4 (53.0–59.8) 30.6 (27.3–34.0)
>800 70.5 (67.5–73.5) 45.2 (41.8–48.6) 21.0 (18.1–23.9)
P for trenda <0.0001 <0.0001 <0.0001
Abbreviations: Cbl: cobalamin; CI: conﬁdence interval.
a Log rank test for trend for survival across the three Cbl level groups.Results from the Cox regression analyses based on multiple
imputations are presented in Table 3. Patients with high Cbl levels
had signiﬁcantly higher mortality than patients with normal Cbl
levels, after adjusting for potential confounders. The difference
was most pronounced for 30-day mortality, comparing mortality
risks among the three Cbl level groups. The difference in MRR
estimates remained statistically signiﬁcant for 31–90-day and
91–365-day mortality. The associations remained similar after
stratifying by sex, age and calendar year (Table 3). The overall 1-
year MRRs (95% CIs) were: 601–800 pmol/L vs. 200–600 pmol/L:
1.7 (1.6–1.8); >800 pmol/L vs. 200–600 pmol/L: 2.3 (2.1–2.5). The
MRRs attenuated with longer follow-up. For MRR estimates on
longer follow-up, please see Supplementary Table S3.
The analyses stratiﬁed by cancer stage also yielded robust
results. As expected, patients with non-localised disease had
poorer survival (Fig. 1B and C), with the same trend for lower
survival probability with higher Cbl levels within strata for cancer
stage (Table 2). Further, MRRs comparing patients with high Cbl
levels to patients with normal Cbl levels were similar for those
with localised versus non-localised cancer for all follow-up
periods, but attenuated with longer follow-up time (Table 3 and
Supplementary Table S3). The MRRs based on multiple imputa-
tions were very comparable to those based on complete case
analysis (for results based on complete case analysis, please see
Supplementary Table S4). For both overall MRRs and stratiﬁed
according to age, sex, calendar year and cancer stage the results
were essentially similar.
Looking at cancer type, we found that patients with elevated Cbl
levels had higher mortality risks for some speciﬁc cancer types,
while other cancers showed null associations (Table 4). The highest
MRR estimates were seen for gastric, colorectal, liver, breast,
prostate and urinary bladder cancer. The estimates were most
predominant in the ﬁrst 30 days when comparing patients with Cbl
>800 pmol/L to those with Cbl levels of 200–600 pmol/L. Most
elevated MRRs estimates attenuated with longer follow-up and
when comparing patients with Cbl levels of 601–800 pmol/L to
those with Cbl levels of 200–600 pmol/L, but we also observed
some elevated MRRs for speciﬁc cancer types for patients with Cbl
levels of 601–800 pmol/L and in follow-up intervals of 31–90 and
91–365 days. None of the cancer types showed a lower mortality
with higher Cbl levels. We also observed some variation in MRR
estimates and wide CIs among the different cancer types and
follow-up intervals. Survival estimates for speciﬁc cancers based
Table 3
Mortality risk ratios and 95% CIs computed by comparing mortality risks for patients with Cbl levels of 601–800 pmol/L and >800 pmol/L, using those with 200–600 pmol/L as
reference. The Cox regression analyses were adjusted for age, sex, calendar year, CCI score and cancer stage, except when the variable was used for stratiﬁcation. These results
are based on multiple imputations to account for missing cancer stage. Lymphatic leukemia and malignant myeloid diseases were not included in the analyses.
30 days 31–90 days 91–365 days
601–800 pmol/L vs.
200–600 pmol/L
>800 pmol/L vs.
200–600 pmol/L
Pa 601–800 pmol/L vs.
200–600 pmol/L
>800 pmol/L vs.
200–600 pmol/L
Pa 601–800 pmol/L vs.
200–600 pmol/L
>800 pmol/L vs.
200–600 pmol/L
Pa
Overall 1.9 (1.6–2.2) 2.7 (2.4–3.1) 0.0003 1.7 (1.5–2.0) 2.4 (2.1–2.7) 0.0005 1.6 (1.4–1.8) 1.9 (1.7–2.2) 0.0179
Sex
Male 1.8 (1.5–2.2) 3.0 (2.5–3.5) 0.0001 1.9 (1.6–2.3) 2.2 (1.8–2.8) 0.2398 1.7 (1.4–2.0) 1.9 (1.6–2.3) 0.2768
Female 2.0 (1.6–2.4) 2.5 (2.1–2.9) 0.0644 1.5 (1.3–1.9) 2.4 (2.0–2.9) 0.0003 1.4 (1.2–1.7) 1.8 (1.6–2.2) 0.0330
Age at diagnosis
0–40 0.0 (.-.) 4.2 (0.9–21.0) 0.9994 0.0 (.-.) 5.2 (0.7–36.5) 0.9984 1.5 (0.4–5.4) 1.8 (0.4–7.6) 0.8880
41–60 3.3 (2.2–4.9) 3.5 (2.3–5.1) 0.8819 1.9 (1.3–2.8) 2.5 (1.7–3.5) 0.3074 1.3 (1.0–1.9) 2.8 (2.1–3.7) 0.0004
61–80 1.8 (1.5–2.2) 2.9 (2.4–3.4) 0.0001 1.8 (1.5–2.1) 2.6 (2.2–3.0) 0.0014 1.6 (1.4–1.8) 1.8 (1.5–2.1) 0.1946
81 1.6 (1.3–2.1) 2.2 (1.8–2.7) 0.0566 1.5 (1.1–2.0) 1.7 (1.3–2.3) 0.4061 1.6 (1.3–2.1) 1.5 (1.1–2.0) 0.6182
Year of diagnosis
2001–
2005
1.7 (1.2–2.2) 2.2 (1.7–2.8) 0.1445 1.8 (1.4–2.4) 2.4 (1.9–3.1) 0.1240 1.9 (1.5–2.4) 1.7 (1.3–2.3) 0.6489
2006–
2010
2.0 (1.7–2.5) 3.0 (2.5–3.6) 0.0011 1.8 (1.5–2.2) 2.3 (1.9–2.8) 0.0855 1.5 (1.3–1.8) 1.9 (1.6–2.3) 0.0798
2011–2013 1.8 (1.4–2.3) 2.8 (2.2–3.5) 0.0098 1.5 (1.2–2.0) 2.4 (1.9–3.1) 0.0055 1.4 (1.2–1.8) 2.0 (1.6–2.5) 0.0203
Cancer stage
Localised 2.0 (1.3–3.1) 3.6 (2.3–5.5) 0.0452 1.7 (1.2–2.5) 2.1 (1.3–3.2) 0.4952 1.7 (1.3–2.2) 2.0 (1.5–2.7) 0.3790
Non-
localised
1.9 (1.6–2.2) 2.6 (2.3–3.0) 0.0002 1.7 (1.5–2.0) 2.4 (2.1–2.7) 0.0007 1.5 (1.3–1.7) 1.9 (1.6–2.2) 0.0222
Abbreviations: Cbl: cobalamin; CCI: Charlson comorbidity index; CI: conﬁdence interval.
a Wald chi-square test for equality in MRR estimates.
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tary Table S5. Survival estimates for lymphatic leukemia and
malignant myeloid diseases (that were analysed separately and
without cancer stage) showed the same dose-response pattern as
the other cancer types in all follow-up strata (Supplementary
Table S5). The MRRs for these two cancer types also showed
essentially the same, although the risk estimates for malignantTable 4
Mortality risk ratios and 95% CIs computed by comparing mortality risks for patients with
reference. The Cox regression analyses were adjusted for age, sex, calendar year, CCI scor
different cancer types. These results are based on multiple imputations to account for
Cancer type 30 days 31–90 days 
601–800 pmol/L vs.
200–600 pmol/L
>800 pmol/L vs.
200–600 pmol/L
Pa 601–800 pmol/L v
200–600 pmol/L
Gastric 1.5 (0.6–3.7) 2.4 (1.1–5.0) 0.4337 0.8 (0.3–2.2) 
Colorectal 1.6 (1.0–2.5) 2.8 (1.9–4.1) 0.0570 2.1 (1.5–3.1) 
Liver 1.2 (0.6–2.5) 3.0 (1.7–5.3) 0.0134 1.5 (0.8–2.6) 
Pancreas 1.4 (0.9–2.1) 1.7 (1.2–2.5) 0.3570 1.2 (0.9–1.8) 
Lung 1.4 (1.1–1.8) 1.9 (1.4–2.4) 0.1322 1.2 (0.9–1.5) 
Breast 3.6 (1.3–10.0) 3.9 (1.3–11.7) 0.9180 1.5 (0.4–4.9) 
Prostate 1.9 (0.7–5.2) 2.8 (1.3–5.9) 0.5335 1.1 (0.3–4.7) 
Kidney 2.9 (1.1–7.5) 0.9 (0.3–3.1) 0.1325 1.0 (0.3–3.4) 
Urinary bladder 0.6 (0.1–2.4) 3.0 (1.3–6.8) 0.0371 0.7 (0.3–2.0) 
Non-Hodgkin
lymphoma
3.2 (1.8–5.7) 1.7 (0.8–3.7) 0.1723 1.6 (0.7–3.5) 
Lymphatic
leukemiab
1.6 (0.2–12.6) 5.1 (1.4–18.7) 0.3260 2.1 (0.5–9.8) 
Malignant
myeloid
diseasesb
1.3 (0.6–2.5) 2.2 (1.4–3.6) 0.1137 1.2 (0.7–2.2) 
Brain and other
CNS tumors
10.0 (1.9–53.1) 8.3 (0.9–77.2) 0.8906 4.3 (0.9–19.5) 
Abbreviations: Cbl: cobalamin; CCI: Charlson comorbidity index; CI: conﬁdence interv
a Wald chi-square test for equality in MRR estimates.
b Lymphatic leukemia and malignant myeloid diseases were not staged, and therefomyeloid diseases attenuated less with increasing follow-up and
were generally lower than for lymphatic leukemia.
For MRRs for speciﬁc cancers based on complete case analysis,
please see Supplementary Table S6. The magnitudeof the association
between high Cbl levels and mortality for some speciﬁc cancers was
slighty attenuated using multiple imputation, but overall, the results
were very comparable. In addition, the use of multiple imputation Cbl levels of 601–800 pmol/L and >800 pmol/L, using those with 200–600 pmol/L as
e and cancer stage. Results are shown according to different follow-up periods and
 missing cancer stage.
91–365 days
s. >800 pmol/L vs.
200–600 pmol/L
Pa 601–800 pmol/L vs.
200–600 pmol/L
>800 pmol/L vs.
200–600 pmol/L
Pa
2.3 (1.2–4.4) 0.0702 1.3 (0.7–2.5) 1.2 (0.6–2.5) 0.9047
2.6 (1.7–3.9) 0.4736 1.6 (1.1–2.2) 2.4 (1.8–3.4) 0.0663
1.6 (0.9–2.9) 0.7650 1.4 (0.8–2.4) 1.4 (0.8–2.5) 0.8530
1.3 (0.9–1.8) 0.9345 1.3 (0.9–1.9) 1.2 (0.8–1.7) 0.6799
1.9 (1.5–2.5) 0.0052 1.2 (1.0–1.5) 1.4 (1.1–1.8) 0.3339
6.6 (3.1–14.3) 0.0248 1.3 (0.6–2.8) 0.9 (0.3–2.5) 0.5598
1.4 (0.4–4.5) 0.8303 2.0 (1.0–3.8) 2.2 (1.2–4.4) 0.8018
2.2 (1.1–4.1) 0.2703 1.4 (0.5–3.8) 2.1 (1.0–4.0) 0.5354
1.5 (0.6–3.5) 0.2813 1.3 (0.7–2.4) 1.5 (0.8–2.9) 0.7165
1.4 (0.6–3.0) 0.7814 1.0 (0.5–1.9) 1.2 (0.7–2.3) 0.5740
5.3 (1.1–25.5) 0.3904 3.0 (1.1–8.1) 1.8 (0.4–7.5) 0.5199
1.2 (0.7–1.9) 0.8334 1.1 (0.7–1.6) 1.4 (1.1–2.0) 0.2382
0.0 (.-.) 0.9834 1.2 (0.3–5.3) 1.8 (0.4–7.8) 0.7065
al.
re not analysed using multiple imputations.
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based on complete case analysis failed.
4. Discussion
This study of more than 80,000 cancer patients demonstrated
that those with elevated plasma Cbl levels prior to diagnosis had
higher mortality, indicating more advanced and aggressive
cancers. These results could not be explained by cancer type,
sex, age, comorbidity or presence of non-localised disease. We
speculate that these associations reﬂect underlying alterations in
the Cbl metabolism caused by the cancer.
Our study has several advantages over earlier studies that
yielded results consistent with ours [9–14]. We examined a large
cohort and were able to adjust for key potential confounders. In
addition, our study can be considered population-based, with
mandatory registration of cancers ensuring complete information
on cancer diagnoses. Comparable Cbl blood test results were
available across the hospital laboratories and during the study
period (data not shown). Further, due to the study’s population-
based design, we were able to identify all cancer patients
diagnosed in Northern Denmark during the study period who
had a Cbl measurement prior to diagnosis. We also included a large
comparison cohort of persons with cancer from Northern
Denmark. Our results remained robust in the stratiﬁed analyses,
most importantly when disaggregated according to cancer stage
and when adjusted for comorbidity. We observed some differences
in age, sex, cancer stage and CCI score, both between the
comparison cohort and the patient cohort and between patients
with different plasma Cbl levels within the patient cohort. This
could provide confounded crude survival estimates. However, all
stratiﬁed analyses showed robust results; that cancer patients with
high plasma Cbl levels had a poorer survival than those with
normal plasma Cbl levels. Further, in the comparative analyses, we
adjusted for the differences in these covariates.
Several issues must be considered when interpreting our
results. First, use of medical registries to investigate research
hypotheses requires accurate and complete coding of information
stored in the registries. Data on diagnoses and prescribed
medications in Danish registries are considered complete and of
high quality [24–27], nearly eliminating the risk of misclassiﬁca-
tion due to information bias. This is substantiated further by the
high comparability of Cbl test results across the study region. Only
cancer stage was not registered completely and was unknown or
missing for 23% of persons in the comparison cohort and for 28–
43% of those in the patient cohort. The incomplete registration of
cancer stage is a study limitation, but multiple imputations were
used to reduce bias in the estimates due to missing cancer stage. In
addition, results were very comparable between complete case
analyses and imputed datasets and did not change the association
found between high Cbl levels and mortality. Risk of selection bias
is also a potential concern. We found the number of patients
included in the study to increase during the study period. While
this could introduce selection bias, analyses stratiﬁed by calendar
year yielded robust results, indicating no substantial bias.
We found that survival among cancer patients with normal Cbl
levels was lower than that among persons with cancer and no pre-
diagnostic Cbl measurement. This indicates that the difference in
survival could be confounded by the indication leading to
physicians’ requests for Cbl measurements. While this can explain
differences in survival between the patient and the comparison
cohorts, we consider it unlikely to be the cause of differences in
survival between patients with high Cbl levels compared to those
with normal levels. We do not believe that the clinical indication
for a requisition is related to a test result showing high Cbl levels. If
a high Cbl test result should make the physician more alert ofpossible cancer, this would, in turn lead to earlier cancer diagnosis
in patients with high Cbl levels and have driven the association
between high Cbl levels and mortality toward the null. Hence, we
conclude that confounding by indication did not inﬂuence the
association between high Cbl levels and mortality in cancer
patients which we found when comparing cancer patients with
different Cbl levels. Ultimately, the actual indication for requesting
a plasma Cbl measurement for the individual patient can only be
speculated, but as outlined, we doubt it could explain the results of
the present study.
We were unable to explore further the association between
elevated Cbl levels and non-localised cancer. Geissbühler et al. [10]
suggested that hepatic metastases in particular are associated with
high Cbl levels. Unfortunately, the registry-based design of our
study precluded collection of information on the exact localisation
of metastases, and the lack of detailed information about cancer
stage is an obvious limitation. Further, when using registry data,
we were unable to identify mortality as cancer speciﬁc. Deaths
from other causes are, however, unlikely to bias the results, given
the fact that the association between mortality and high Cbl levels
revealed mainly an elevated risk in the short term and was
adjusted for comorbidity. Also, the registry data precluded the
assessment of possible confounding from life-style factors, since
such data are not recorded. While smoking does not affect Cbl
metabolism [36], alcohol and alcohol-related liver disease is
known to cause high Cbl levels [4]. Thus, both liver metastases and
benign liver disease could inﬂuence the results. Additionally, we
did not include results from other biochemical tests in our study.
While inclusion of such test results possibly could have helped to
identify other potential prognostic biomarkers, it would also have
increased the probability of confounding by indication, since the
laboratory tests found in the LABKA database are performed only at
the request of a physician. Furthermore, data on ethnicity are not
available from the registries. While racial differences in plasma Cbl
levels have been reported [37], the Danish population is fairly
homogenous and consists mainly of Caucasians.
The underlying pathogenesis leading to high Cbl levels in cancer
patients is not fully understood. Previous studies have shown
elevated non-cancer mortality [11,15–19], pointing to a pathogen-
esis related not only to the cancer itself. Our results are unlikely to
be related to diet, since the intestinal absorptive capacity for a
regular diet and low-dose vitamin supplements is not thought to
give rise to high Cbl levels [38]. This also justiﬁes why we chose not
to include data on medication considered to lower Cbl levels, such
as metformin or proton pump inhibitors, because these drugs are
thought to affect Cbl absorption and metabolism in the long term,
and thus are unlikely to affect the short-term associations in this
study [39,40]. High-dose Cbl drugs can induce elevated Cbl levels
[29], but patients treated with such drugs were excluded from our
study.
Altered Cbl metabolism is likely to be an underlying factor for
our results. We speculate that cancer causes changes in the Cbl
metabolism which then give rise to high plasma Cbl levels. Our
interpretation is thus that the cancer somehow induces high Cbl
levels, not that high Cbl levels cause cancer or promote a more
aggressive cancer. This assumption is based both on the current
results and on our previous observations that cancer risk was
elevated mainly within the ﬁrst year after plasma Cbl measure-
ment [3] and that one particular Cbl-binding protein, haptocorrin,
was found to be elevated in patients with high Cbl levels, including
cancer patients [4]. Since circulating Cbl is exclusively protein-
bound, and haptocorrin is metabolised solely in the liver,
alterations in the Cbl metabolism may involve the liver. The
ﬁnding of higher mortality also in patients with localised cancer
implies that other mechanisms could underlie the association. It is
known that both circulating and tissue-resident inﬂammatory cells
164 J.F.H. Arendt et al. / Cancer Epidemiology 40 (2016) 158–165can produce Cbl-binding proteins, including haptocorrin [2]. Thus,
the association between high Cbl levels and aggressive cancer
could involve a pronounced inﬂammatory response to the cancer.
We observed that some cancer types showed a stronger association
than others between high Cbl levels and mortality. However, no
protective effect of high Cbl levels was observed for any of the
cancer types. The statistically imprecise estimates for speciﬁc
cancers were difﬁcult to interpret, also precluding stage-stratiﬁed
analyses for each cancer type. Ultimately, further studies are
warranted that could also elucidate the possible alterations in the
Cbl metabolism and help to identify particular clinical settings, in
which evaluation of Cbl levels is relevant for cancer patients. One
way of evaluating plasma Cbl as a prognostic marker, and at the
same time come closer to an understanding of the alterations in Cbl
metabolism in cancer patients, would be to set up prospective
studies. In this way, patients could undergo continous measure-
ments of plasma Cbl levels and the levels of Cbl binding proteins.
This would make it possible to evaluate the levels during the
course of disease, and to assess the association with treatment
response and markers of disease activity and any possible
inﬂammatory response.
Our study lends strong support to earlier studies demonstrating
that elevated Cbl levels were associated with lower cancer survival
compared to those with normal Cbl levels. We found the
association to be particularly pronounced for short-term mortality,
and it showed a dose-response pattern. Our study suggests that
high Cbl levels may be a potential biomarker for cancer prognosis.
However, further prospective studies are needed to establish the
clinical applicability of plasma Cbl levels as a prognostic biomarker.
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